Andrew Holmes1, Rainer Spanagel, John H Krystal. 1. Laboratory of Behavioral and Genomic Neuroscience, National Institute on Alcohol Abuse and Alcoholism, NIH, Bethesda, MD, USA, holmesan@mail.nih.gov.
Abstract
RATIONALE: An increasingly compelling literature points to a major role for the glutamate system in mediating the effects of alcohol on behavior and the pathophysiology of alcoholism. Preclinical studies indicate that glutamate signaling mediates certain aspects of ethanol's intoxicating and rewarding effects, and undergoes adaptations following chronic alcohol exposure that may contribute to the withdrawal, craving and compulsive drug-seeking that drive alcohol abuse and alcoholism. OBJECTIVES: We discuss the potential for targeting the glutamate system as a novel pharmacotherapeutic approach to treating alcohol use disorders, focusing on five major components of the glutamate system: the N-methyl-D-aspartate (NMDA) receptor and specific NMDA subunits, the glycineB site on the NMDA receptors (NMDAR), L-alpha-amino-3-hydroxy-5-methyl-isoxazole-4-propionic acid ionotropic (AMPA) and kainate (KAR) receptors, metabotropic receptors (mGluR), and glutamate transporters. RESULTS: Chronic alcohol abuse produces a hyperglutamatergic state, characterized by elevated extracellular glutamate and altered glutamate receptors and transporters. Pharmacologically manipulating glutamatergic neurotransmission alters alcohol-related behaviors including intoxication, withdrawal, and alcohol-seeking, in rodents and human subjects. Blocking NMDA and AMPA receptors reduces alcohol consumption in rodents, but side-effects may limit this as a therapeutic approach. Selectively targeting NMDA and AMPA receptor subunits (e.g., GluN2B, GluA3), or the NMDAR glycineB site offers an alternative approach. Blocking mGluR5 potently affects various alcohol-related behaviors in rodents, and mGluR2/3 agonism also suppresses alcohol consumption. Finally, glutamate transporter upregulation may mitigate behavioral and neurotoxic sequelae of excess glutamate caused by alcohol. CONCLUSIONS: Despite the many challenges that remain, targeting the glutamate system offers genuine promise for developing new treatments for alcoholism.
RATIONALE: An increasingly compelling literature points to a major role for the glutamate system in mediating the effects of alcohol on behavior and the pathophysiology of alcoholism. Preclinical studies indicate that glutamate signaling mediates certain aspects of ethanol's intoxicating and rewarding effects, and undergoes adaptations following chronic alcohol exposure that may contribute to the withdrawal, craving and compulsive drug-seeking that drive alcohol abuse and alcoholism. OBJECTIVES: We discuss the potential for targeting the glutamate system as a novel pharmacotherapeutic approach to treating alcohol use disorders, focusing on five major components of the glutamate system: the N-methyl-D-aspartate (NMDA) receptor and specific NMDA subunits, the glycineB site on the NMDA receptors (NMDAR), L-alpha-amino-3-hydroxy-5-methyl-isoxazole-4-propionic acid ionotropic (AMPA) and kainate (KAR) receptors, metabotropic receptors (mGluR), and glutamate transporters. RESULTS:Chronic alcohol abuse produces a hyperglutamatergic state, characterized by elevated extracellular glutamate and altered glutamate receptors and transporters. Pharmacologically manipulating glutamatergic neurotransmission alters alcohol-related behaviors including intoxication, withdrawal, and alcohol-seeking, in rodents and human subjects. Blocking NMDA and AMPA receptors reduces alcohol consumption in rodents, but side-effects may limit this as a therapeutic approach. Selectively targeting NMDA and AMPA receptor subunits (e.g., GluN2B, GluA3), or the NMDARglycineB site offers an alternative approach. Blocking mGluR5 potently affects various alcohol-related behaviors in rodents, and mGluR2/3 agonism also suppresses alcohol consumption. Finally, glutamate transporter upregulation may mitigate behavioral and neurotoxic sequelae of excess glutamate caused by alcohol. CONCLUSIONS: Despite the many challenges that remain, targeting the glutamate system offers genuine promise for developing new treatments for alcoholism.
Authors: Clyde W Hodge; Michael F Miles; Amanda C Sharko; Rebekah A Stevenson; Jennie R Hillmann; Veronique Lepoutre; Joyce Besheer; Jason P Schroeder Journal: Psychopharmacology (Berl) Date: 2005-11-15 Impact factor: 4.530
Authors: Daniel T Christian; Nancy J Alexander; Marvin R Diaz; Stacey Robinson; Brian A McCool Journal: Neuropharmacology Date: 2012-02-22 Impact factor: 5.250
Authors: R K Fuller; L Branchey; D R Brightwell; R M Derman; C D Emrick; F L Iber; K E James; R B Lacoursiere; K K Lee; I Lowenstam Journal: JAMA Date: 1986-09-19 Impact factor: 56.272
Authors: Gunter Schumann; Monika Johann; Josef Frank; Ulrich Preuss; Norbert Dahmen; Manfred Laucht; Marcella Rietschel; Dan Rujescu; Anbarasu Lourdusamy; Toni-Kim Clarke; Kristina Krause; Anne Dyer; Martin Depner; Stefan Wellek; Jens Treutlein; Armin Szegedi; Ina Giegling; Sven Cichon; Dorothea Blomeyer; Andreas Heinz; Simon Heath; Mark Lathrop; Norbert Wodarz; Michael Soyka; Rainer Spanagel; Karl Mann Journal: Arch Gen Psychiatry Date: 2008-07
Authors: Suchitra Krishnan-Sarin; Stephanie S O'Malley; Nicholas Franco; Dana A Cavallo; Meghan Morean; Julia Shi; Brian Pittman; John H Krystal Journal: Alcohol Clin Exp Res Date: 2015-02-09 Impact factor: 3.455
Authors: Nicholas J Jury; Anna K Radke; Dipanwita Pati; Adrina Kocharian; Masayoshi Mishina; Thomas L Kash; Andrew Holmes Journal: Behav Brain Res Date: 2018-06-25 Impact factor: 3.332
Authors: Erica N Grodin; Spencer Bujarski; Alexandra Venegas; Wave-Ananda Baskerville; Steven J Nieto; J David Jentsch; Lara A Ray Journal: Alcohol Alcohol Date: 2019-12-01 Impact factor: 2.826